Table 1.
Patient characteristics.
| Parameter | PLWHEC | PLWHART | HC | P-values |
|---|---|---|---|---|
| N | 14 | 54 | 18 | ND |
| Gender: Female, N (%) | 7 (50) | 19 (35) | 9 (50) | ND |
| Ethnicity, N (%) | ||||
| Black | 9 (64.2) | 21 (38.8) | 5 (27.7) | ND |
| Asian | – | 2 (3.7) | – | |
| Caucasian | 4 (28.6) | 31 (57.4) | 13 (72.2) | |
| Hispanic | 1 (7.1) | – | – | |
| At sampling | ||||
| Age in years, mean (SD) | 46 (10.5) | 50 (9.5) | 47 (9) | 0.2704a |
| CD4+ T cell count (cells/µL); median (IQR) | 680 (570–1060) | 660 (485–795) | NA | 0.5012b |
| CD8+ T cell count (cells/µL); median (IQR) | 900 (540–1330) | 600 (415–950) | NA | 0.0974b |
| CD4:CD8 ratio; median (IQR) | 1 (0.44–1.18) | 1 (0.7–1.45) | NA | 0.3295b |
| Duration of treatment in years; median (IQR) | NA | 8 (6.75–19) | NA | ND |
| Duration of suppressive treatment in years; median (IQR) | NA | 8 (7–15) | NA | ND |
| Years HIV positive; median (IQR) | 7 (4.5–11.7) | 12.5 (9–20) | NA | 0.0012b |
|
HIV RNA load; Copies/mL (IQR) |
<40 copies/mL | <40 copies/mL | NA | ND |
| Treatment regimen, N (%) | ||||
| 3rd drug, | ||||
| Boosted PI | 2 (3.7) | |||
| INSTI | 30 (55.5) | |||
| NNRTI | NA | 21 (38.8) | NA | NA |
| 1st drug, | ||||
| ABC | 34 (62.9) | |||
| TAF/TDF | 16 (29.6) | |||
| Other | 4 (7.4) | |||
| Initiation of treatment | ||||
| CD4+ T cell count at treatment initiation (cells/µL); median (IQR) | NA | 351 (167.5–522.5) | NA | ND |
| Viral Load at treatment initiation; Log10 copies/mL (IQR) | NA | 4.79 (4.06–5.44) | NA | ND |
ABC abacavir, IQR interquartile range, N number, NA not applicable, ND not done, PI protease inhibitor, INSTI integrase strand transfer inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, SD standard deviation, TAF tenofovir alafenamide, TDF tenofovir disoproxil.
aOne-way ANOVA.
bMann–Whitney test.